PCSK9 and coronary artery disorder: Preclinical data suggest that PCSK9 promotes proinflammatory cytokine release, vascular smooth muscle cell proliferation, and impaired endothelial repair-mechanisms implicated in adverse vascular responses after PCI.<h4>Aim</h4>To determine whether proactive, short-term evolocumab improves outcomes in patients with coronary artery disease at high residual risk after PCI.<h4>Methods</h4>The HANYANG-PICK trial is a prospective, randomized, open-label, multicenter study enrolling patients with post-PCI <sub>max</sub>LCBI<sub>4mm</sub> ≥200 on NIRS-IVUS.